FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 1287 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Longtime NPR Reporter Shares Diagnosis to Bring More Awareness to Metastatic... June 26, 2021 Repurposing radiotherapy drugs could give immunotherapy a boost November 11, 2022 How My Cancer Diagnosis at Age 17 Changed My Perspective on... December 14, 2020 EMA Recommends Granting a Marketing Authorisation for Tebentafusp March 31, 2022 Load more HOT NEWS No Survival Benefit for Adding Adjuvant Chemotherapy to Endocrine Therapy in... FDA Approves Safety Labelling Changes Regarding DPD Deficiency for Fluorouracil Injection... Alternatives for Outdoor Foods Darolutamide Maintenance Improves Outcomes in Patients with mCRPC Who Were Previously...
